
RANI Stock Forecast & Price Target
RANI Analyst Ratings
Bulls say
Rani Therapeutics Holdings Inc. has demonstrated the ability of its RaniPill technology to successfully and consistently deliver biologics orally with enhanced bioavailability, supporting its advancement toward human trials in 2025. The partnership with Chugai reflects strong validation from a major player in the pharmaceutical industry and positions Rani to capture a significant market opportunity in the oral drug delivery space. Additionally, the company's robust financial position, with a cash runway extending through 2028, provides the necessary resources to advance its development programs, particularly RT-114, which may attract a larger audience in the obesity treatment market.
Bears say
Rani Therapeutics Holdings Inc. faces a negative outlook primarily due to concerns surrounding its revenue forecasts, which may be adversely impacted by competition within the biotherapeutics market and the company's ability to secure necessary reimbursement levels for its innovative drug delivery methods. Despite the substantial safety data supporting the RaniPill platform, the value attributed to it remains modest, indicating a potential disconnect between market perception and commercial viability. Furthermore, the risk of failures in future clinical trials poses an additional threat to Rani's forecasts, further contributing to investor skepticism regarding the company’s long-term financial performance.
This aggregate rating is based on analysts' research of Rani Therapeutics Holdings and is not a guaranteed prediction by Public.com or investment advice.
RANI Analyst Forecast & Price Prediction
Start investing in RANI
Order type
Buy in
Order amount
Est. shares
0 shares